Form 4: TELA Bio CBO Firestone Boosts Equity Holdings

TELA Bio's Chief Business Officer, Gregory A. Firestone, reported significant equity awards including 37,000 restricted stock units and 55,000 stock options, alongside routine tax-related share dispositions.

Summary

• Gregory A. Firestone, Chief Business Officer of TELA Bio, Inc., reported transactions involving the company's common stock and stock options.
• On February 20, 2026, Firestone acquired 37,000 restricted stock units (RSUs) at a price of $0.
• These RSUs will vest in four equal annual installments, commencing on February 20, 2027, contingent on his continuous service.
• Also on February 20, 2026, Firestone was granted 55,000 stock options with an exercise price of $0.717.
• These options vest 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the subsequent 36 calendar months, subject to continued service, and expire on February 20, 2036.
• Following these acquisitions, Firestone's beneficial ownership of common stock was 144,848 shares.
• On February 21, 2026, 4,189 shares of common stock were disposed of at $0.7174 to satisfy withholding taxes upon RSU vesting, reducing beneficial ownership to 140,659 shares.
• On February 23, 2026, an additional 1,352 shares of common stock were disposed of at $0.766 for tax withholding purposes, resulting in a beneficial ownership of 139,307 shares.
• The reported beneficial ownership includes 1,058 shares acquired under the Company's employee stock purchase plan on January 30, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it reflects a significant equity grant to a key executive, aligning his incentives with long-term company performance, despite the routine tax-related share dispositions.

Positives

• Chief Business Officer Gregory A. Firestone was granted 37,000 restricted stock units (RSUs), aligning his interests with long-term shareholder value.
• Firestone also received 55,000 stock options, providing further incentive for company performance and potential future equity upside.
• The acquisition of 1,058 shares through the employee stock purchase plan on January 30, 2026, indicates ongoing employee investment in the company.

Negatives

• A total of 5,541 shares (4,189 shares at $0.7174 and 1,352 shares at $0.766) were disposed of to cover tax withholding obligations related to RSU vesting, which represents a reduction in direct share ownership.

Future Outlook

The vesting schedules for the granted restricted stock units and stock options extend through February 2027 and beyond, indicating a long-term incentive structure tied to the reporting person's continued service.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the Chief Business Officer are a standard practice in the biotechnology and medical device industries, such as TELA Bio, to attract, retain, and incentivize leadership. These grants typically align executive compensation with long-term company performance and shareholder interests, a common strategy seen across peers like Integra LifeSciences or Organogenesis Holdings.

Comparison to Industry Standards

• Equity compensation packages, including RSUs and stock options, are standard practice for executive retention and motivation in the medical technology sector.
• The vesting schedules, with initial cliff vesting followed by monthly installments, are typical for long-term incentive plans in companies comparable to TELA Bio, such as those observed at smaller to mid-cap biotech firms like AxoGen, Inc. or Vericel Corporation.
• The exercise price of $0.717 for the stock options is consistent with the market price at the time of grant, a common feature of at-the-money options designed to reward future stock price appreciation.

Related Party Transactions

• The reported transactions involve equity awards granted by TELA Bio, Inc. to its Chief Business Officer, Gregory A. Firestone, which are considered related party transactions in the context of executive compensation.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Business Officer's interests with long-term shareholder value, potentially incentivizing performance that drives stock price appreciation. The tax-related dispositions are routine and have minimal direct impact on the company's capital structure.
• Employees: The mention of shares acquired under the employee stock purchase plan indicates a broader program for employee equity participation.

Next Steps

• The 37,000 RSUs will begin vesting in four equal annual installments starting February 20, 2027.
• The 55,000 stock options will vest 25% on February 20, 2027, with the remainder vesting monthly over the subsequent 36 months.

Key Dates

Recommendation

While the equity grants to a key executive are a positive signal of alignment and incentive, this Form 4 filing primarily details routine compensation events rather than new strategic developments or significant shifts in company fundamentals. The tax-related dispositions are expected. Therefore, a 'hold' recommendation is appropriate, awaiting further operational or financial updates to assess the company's trajectory.

Keywords

TELA Bio, TELA, Gregory A. Firestone, Chief Business Officer, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, Beneficial Ownership